<DOC>
	<DOCNO>NCT01392443</DOCNO>
	<brief_summary>The objective study determine efficacy INC424 assess reduction spleen volume patient primary myelofibrosis ( MF ) , post-polycythemia vera ( PV ) MF , post-essential thrombocythemia ( ET ) MF . The safety tolerability INC424 effect INC424 patient report outcomes duration response assess reduction spleen volume also assess .</brief_summary>
	<brief_title>Asian Phase II Study INC424 Patients With Primary Myelofibrosis ( MF ) , Post-PV MF Post-ET MF</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>1 . 18 year old 2 . Diagnosis primary myelofibrosis ( MF ) , postpolycythemia vera ( PV ) MF , postessential thrombocythemia ( ET ) MF 3 . Enlarged spleen , measure 5 cm great costal margin 4 . Must two follow risk factor : 1 . Over 65 year old 2 . Have follow symptom often associate MF : loss weight , fever , night sweat 3 . Have low red blood cell count ( anemia hemoglobin &lt; 10 g/dL ) 4 . Have high white blood cell count ( history white blood cell count &gt; 25,000/uL ) 5 . Have high circulating blast ( &gt; = 1 % ) measure blood test 5 . Should circulate blast &lt; 10 % ( measure blood test ) 6 . Should capable selfcare 7 . Should adequate bone marrow reserve 8 . Should option stem cell transplantation 9 . Should discontinue prior ongoing treatment myelofibrosis prior enter study 10 . Had prior treatment another JAK inhibitor 1 . Does adequate liver kidney function ( measure blood test ) 2 . Has active infection ( bacterial , viral , etc . ) 3 . Has active hepatitis A , B , C positive HIV 4 . Has another cancer need active intervention 5 . Had history bleed disorder 6 . Had history low platelet count ( measure blood test ) relate treatment MF 7 . Had radiation spleen within 1 year joining study 8 . Does adequate heart function 9 . Sufficient time elapse stop previous treatment MF joining study 10 . Females pregnant breastfeed 11 . Not able sign inform consent 12 . Has active medical condition doctor deems may compromise safety ability join study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>INC424</keyword>
	<keyword>Ruxolitinib</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>MF</keyword>
</DOC>